LDS/Medical Tests/Targeted Gene Mutation Panel, Solid Organ Neoplasm (PancreaSeq)

Targeted Gene Mutation Panel, Solid Organ Neoplasm (PancreaSeq)

Pancreatic cancer is the 4th leading cause of cancer-related deaths worldwide, accounting for approximately 227,000 deaths annually. Genetic risk factors are believed to account for 10-15% of pancreatic cancer. Early signs of pancreatic cancer are uncommon but may include the presence of pancreatic cyst(s) that are only detected by imaging procedures. Characterization of pancreatic cysts are important to evaluated for pancreatic cancer. Pancreaseq is a genetic test that involves next-generation sequencing (NGS) technology to assess single-nucleotide polymorphisms (SNPs) in the DNA/ mRNA of 74 genes associated with the risk of pancreatic cancer. The test further allows the classification of pancreatic cysts.

Pancreaseq screens for gene mutations, fusions, copy number alterations, neuroendocrine markers, and CEA RNA expression (by qRT-PCR) in genes KRAS, GNAS, RNF43, SMAD4, TP53, PTEN, VHL, NF2 tumor suppressor genes, ALK, BRAF, FGFR2, NTRK1, NTRK3, RET, ROS1, RAF1, PRKCA, PRKCB, and KRT7, KRT20, CHRGR, and PGK1 present in the pancreatic cyst fluid aspirate. The test further offers the classification of the pancreatic cyst into intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasms (MCN), which are the precursor of pancreatic ductal adenocarcinoma. Pancreaseq additionally analyses the CEACAM5 gene mRNA expression to evaluate the carcinoembryonic antigen (CEA) up-regulation in pancreatic cancer.

  • Aids in the characterization of pancreatic cysts
  • Aids in the evaluation of patients with pancreatic cancer
  • Useful in screening family members with a history of pancreatic cancer
  • Gene mutations: positive/ negative
  • Gene fusions: positive/ negative
  • Copy number alteration: positive/ negative
  • Neuroendocrine markers: positive/ negative
  • CEA mRNA expression: 0 gene expression unit (GEU)
  • Type of cyst: intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasms (MCN) 

A positive result is suggestive of a neoplastic pancreatic cyst. 

A negative result is suggestive of a non-neoplastic pancreatic cyst.

Finding Result
Overall interpretation Negative (Likely non-neoplastic)
Gene mutations Negative
Gene fusions Negative
Copy number alteration Negative
Neuroendocrine markers Negative
CEA mRNA expression 0 gene expression unit (GEU)
Next-generation sequencing (NGS) and qRT-PCR.

Pancreatic cyst fluid.

Stability

  • Ambient: 3 days
  • Refrigerated: 1 week
  • Frozen: unstable
Serum CEA, lipase, amylase, glucose, insulin, ALT, AST, pancreatic biopsy, elastase.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login